{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:35:11Z","timestamp":1762508111090},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00277-020-04101-7","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T20:03:07Z","timestamp":1590436987000},"page":"1627-1634","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Results of R-ESHAP as salvage therapy in refractory\/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group"],"prefix":"10.1007","volume":"99","author":[{"given":"A.","family":"Munta\u00f1ola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mercadal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Escoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Iserte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Canet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Magnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sorigu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Salar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"4101_CR1","unstructured":"Swerdlow S, Campo E, Harris NL. et al. Follicular Lymphoma. WHO Classification of tumours of haematopoietic and lymphoid tissues. Revised 4th Edition, 266-273. 2017."},{"key":"4101_CR2","doi-asserted-by":"publisher","unstructured":"Tan D, Horning SJ, Hoppe RT. Levy R, Rosenberg SA, Sigal BM, Warnke RA, Natkunam Y, Han SS, Yuen A, Plevritis SK, Advani RH. (2013) Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Standford University experience. Blood. ;122(6):981-987. https:\/\/doi.org\/10.1182\/blood-2013-03-491514.","DOI":"10.1182\/blood-2013-03-491514"},{"issue":"3","key":"4101_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/bjh.15805","volume":"185","author":"L Magnano","year":"2019","unstructured":"Magnano L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, Munta\u00f1ola A, Nadeu F, Setoain X, Rodr\u00edguez S, Andrade-Campos M, Espinosa-Lara N, Rodr\u00edguez G, Sancho JM, Moreno M, Mercadal S, Carro I, Salar A, Garcia-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Jim\u00e9nez-Ubieto A, Rodriguez A, Gonz\u00e1lez de Villambros\u00eda S, Bello JL, L\u00f3pez L, Novelli S, de Cabo E, Infante ME, Pardal E, Monsalvo S, Gonz\u00e1lez M, Mart\u00edn A, Caballero MD, L\u00f3pez-Guillermo A, Grupo Espa\u00f1ol de Linfomas y Trasplante Aut\u00f3logo de M\u00e9dula \u00d3sea (GELTAMO) (2019) Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol 185(3):480\u2013491. https:\/\/doi.org\/10.1111\/bjh.15805","journal-title":"Br J Haematol"},{"issue":"11","key":"4101_CR4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Bachy E, Ghesqui\u00e8res H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Cl\u00e9ment C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK (2016) Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am JHematol 91(11):1096\u20131101. https:\/\/doi.org\/10.1002\/ajh.24492","journal-title":"Am JHematol"},{"issue":"5","key":"4101_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bjh.15708","volume":"184","author":"A Rivas-Delgado","year":"2019","unstructured":"Rivas-Delgado A, Magnano L, Moreno-Vel\u00e1zquez M, Garcia O, Nadeu F, Mozas P, Dlouhy I, Baumann T, Rovira J, Gonz\u00e1lez-Farr\u00e9 B, Mart\u00ednez A, Balagu\u00e9 O, Delgado J, Villamor N, Gin\u00e9 E, Campo E, Sancho-C\u00eda JM, L\u00f3pez-Guillermo A (2019) Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol 184(5):753\u2013759. https:\/\/doi.org\/10.1111\/bjh.15708","journal-title":"Br J Haematol"},{"issue":"5","key":"4101_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/17474086.2018","volume":"11","author":"T Erblich","year":"2018","unstructured":"Erblich T, Montoto S (2018) Treating relapsed follicular lymphoma. Expert Rev Hematol 11(5):403\u2013410. https:\/\/doi.org\/10.1080\/17474086.2018","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"4101_CR7","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3324\/haematol.13440","volume":"93","author":"A Martin","year":"2008","unstructured":"Martin A, Conde E, Arn\u00e1n M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, Garc\u00eda-Sanchez P, V\u00e1zquez L, Nistal S, Requena MJ, Donato EM, Gonz\u00e1lez JA, Le\u00f3n A, Ruiz C, Grande C, Gonz\u00e1lez-Barca E, Caballero MD, Grupo Espa\u00f1ol de Linfomas\/Trasplante Aut\u00f3logo de M\u00e9dula Osea (GEL\/TAMO Cooperative Group) (2008) R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study. Haematologica 93(12):1829\u20131836. https:\/\/doi.org\/10.3324\/haematol.13440","journal-title":"Haematologica"},{"issue":"1","key":"4101_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1179\/joc.2010.22.1.54","volume":"22","author":"K Ueda","year":"2010","unstructured":"Ueda K, Nannya Y, Asai T, Amamoto G, Hangaishi A, Takahashi T, Imai T, Kurokawa M (2010) Efficacy and safety of modified rituximab-ESHAP therapy for relapsed\/refractory B-cell lymphoma. J Chemother 2010 22(1):54\u201357. https:\/\/doi.org\/10.1179\/joc.2010.22.1.54","journal-title":"J Chemother 2010"},{"issue":"4","key":"4101_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3816\/CLML.2010.n.055","volume":"10","author":"J Lignon","year":"2010","unstructured":"Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J, Mounier N, Gisselbrecht C, Faure P, Thieblemont C (2010) Rituximab, dexamethasone, cytarabine and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed\/refractory B-cell Non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10(4):262\u2013269. https:\/\/doi.org\/10.3816\/CLML.2010.n.055","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"4101_CR10","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-L\u00f3pez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244\u20131253. https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1244","journal-title":"J Clin Oncol"},{"issue":"31","key":"4101_CR11","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 32(31):3490\u20133496. https:\/\/doi.org\/10.1200\/JCO.2013.53.9593","journal-title":"J Clin Oncol"},{"issue":"27","key":"4101_CR12","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Bri\u00e8re J, Moskowitz CH, Schmitz N (2010) R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 28(27):4184\u20134190. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol"},{"key":"4101_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11912-009-0052-0","volume":"11","author":"C Thieblemont","year":"2009","unstructured":"Thieblemont C, Gisselbrecht C (2009) Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr Oncol Rep 2009 11:386\u2013393. https:\/\/doi.org\/10.1007\/s11912-009-0052-0","journal-title":"Curr Oncol Rep 2009"},{"key":"4101_CR14","doi-asserted-by":"crossref","unstructured":"Pettengell R, Uddin R, Boumendil A. et al. (2017) Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT Lymphoma Working Party LYM1 trial. 15th International Conference on Malignant Lymphoma (ICML)","DOI":"10.1002\/hon.2437_13"},{"issue":"21","key":"4101_CR15","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G (2003) High-dose therapy improves progression free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol 21(21):3918\u20133927. https:\/\/doi.org\/10.1200\/JCO.2003.10.023","journal-title":"J Clin Oncol"},{"issue":"6","key":"4101_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","volume":"24","author":"C Casulo","year":"2018","unstructured":"Casulo C, Friedberg JW, Ahn KW, Zhou X, Farber CM, Flowers CR, Hainsworth JF, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW (2018) Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 24(6):1163\u20131171. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.771","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"4101_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/hon.2553","volume":"12","author":"A Jim\u00e9nez-Ubieto","year":"2019","unstructured":"Jim\u00e9nez-Ubieto A, Grande C, Caballero D, Ya\u00f1ez L, Novelli S, Hern\u00e1ndez-Garc\u00eda MT, Manzanares M, Arranz R, Ferrerio JJ, Bobillo S, Mercadal S et al (2019) Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy. Hematol Oncol Stem Cell Ther 12(4):194\u2013120. https:\/\/doi.org\/10.1002\/hon.2553","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"7","key":"4101_CR18","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","volume":"98","author":"S Montoto","year":"2013","unstructured":"Montoto S, Corradini P, Dreyling M et al (2013) Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 98(7):1014\u20131021. https:\/\/doi.org\/10.3324\/haematol.2013.084723","journal-title":"Haematologica"},{"issue":"31","key":"4101_CR19","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","volume":"29","author":"C Thieblemont","year":"2011","unstructured":"Thieblemont C, Briere J, Mounier N (2011) The germinal center\/activated B cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 29(31):4079\u20134087. https:\/\/doi.org\/10.1200\/JCO.2011.35.4423","journal-title":"J Clin Oncol"},{"key":"4101_CR20","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/jco.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber C, Flowers C, Hainsworth J, Maurer M, Cerhan J, Link B, Zelenetz A, Friedberg J (2015) (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis fromthe National LymphoCare Study. J Clin Oncol 33:2516\u20132522. https:\/\/doi.org\/10.1200\/jco.2014.59.7534","journal-title":"J Clin Oncol"},{"key":"4101_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston N, Schuster S, Jurczak W, Flinn I, Flowers C, Martin P, Viardot A, Blum K, Goy A, Davies A, Zinzani PL, Dreyling M, Johnson D, Miller L, Holes L, Li D, Dansey R, Godfrey W, Salles G (2014) PI3K delta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370:1008\u20131018. https:\/\/doi.org\/10.1056\/NEJMoa1314583","journal-title":"N Engl J Med"},{"issue":"5","key":"4101_CR22","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/bjh.15057","volume":"183","author":"P Guione","year":"2018","unstructured":"Guione P, Cavallo F, Visco C, Chen Z, Castellino A, Tisi M, Dogliotti I, Nicolosi M, Boccadoro M, Leonard J, Vitolo U, Martin P (2018) A retrospective study of RDHAP\/Ox for early progressing follicular lymphoma. Br J Haematol 183(5):828\u2013831. https:\/\/doi.org\/10.1111\/bjh.15057","journal-title":"Br J Haematol"},{"issue":"16","key":"4101_CR23","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1002\/cam4.2555","volume":"8","author":"FJ Pe\u00f1alver","year":"2019","unstructured":"Pe\u00f1alver FJ, M\u00e1rquez JA, Dur\u00e1n S, Giraldo P, Mart\u00edn A, Montalb\u00e1n C, Sancho JM, Ram\u00edrez MJ, Terol MJ, Capote FJ, Guti\u00e9rrez A, S\u00e1nchez B, L\u00f3pez A, Salar A, Rodr\u00edguez-Caravaca G, Canales M, Caballero D (2019) Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. Cancer Med 8(16):6955\u20136966. https:\/\/doi.org\/10.1002\/cam4.2555","journal-title":"Cancer Med"},{"issue":"13","key":"4101_CR24","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2008","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, B\u00f6ck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, H\u00e4nel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W (2008) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13):4003\u20134008. https:\/\/doi.org\/10.1182\/blood-2006-04-016725","journal-title":"Blood"},{"key":"4101_CR25","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman M, Emmanouillides C, Pohlman R, Bartlett N, Wiseman G, Padre N, Grillo-L\u00f3pez A, Multani P, White C (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:2453\u20132463. https:\/\/doi.org\/10.1200\/JCO.2002.11.076","journal-title":"J Clin Oncol"},{"issue":"8","key":"4101_CR26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben L, Lennard A, Lugtenburg P, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson B (2016) Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximabrefractory indolent non-Hodgkin lymphoma (GADOLIN): a randomized, controlled, open-label, multicenter, phase 3 trial. Lancet Oncol 17(8):1081\u20131093. https:\/\/doi.org\/10.1016\/S1470-2045(16)30097-3","journal-title":"Lancet Oncol"},{"issue":"22","key":"4101_CR27","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/jco.2017.76.3656","volume":"36","author":"BD Cheson","year":"2018","unstructured":"Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben L, Lennard A, Lugtenburg P, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn L (2018) Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 36(22):2259\u20132266. https:\/\/doi.org\/10.1200\/jco.2017.76.3656","journal-title":"J Clin Oncol"},{"issue":"35","key":"4101_CR28","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/jco.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, Leppa S, Follows G, Lenz G, Seog Kim W, Nagler A, Panagiotidis P, Demeter J, \u00d6zcan M, Kosinova M, Zinzani PL (2017) Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 35(35):3898\u20133905. https:\/\/doi.org\/10.1200\/jco.2017.75.4648","journal-title":"J Clin Oncol"},{"key":"4101_CR29","doi-asserted-by":"publisher","unstructured":"Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline S, Mayer S, Merli M, Lunin S, Pettitt A, Nagy Z, Tournilhac O\u2026et Zinzani PL. (2019) DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. ;37(11):912-922. https:\/\/doi.org\/10.1200\/jco.18.00915.","DOI":"10.1200\/jco.18.00915"},{"issue":"32","key":"4101_CR30","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1200\/jco.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis J, Vose J (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 27(32):5404\u20135409. https:\/\/doi.org\/10.1200\/jco.2008.21.1169","journal-title":"J Clin Oncol"},{"issue":"14","key":"4101_CR31","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/jco.19.00010","volume":"37","author":"J Leonard","year":"2019","unstructured":"Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn I, Moreira C, Cabe\u00e7ades J, Liu D, Kalambakas S, Fustier P, Nu C, Gribben J (2019) AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 37(14):1188\u20131199. https:\/\/doi.org\/10.1200\/jco.19.00010","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04101-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04101-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04101-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T23:24:12Z","timestamp":1621898652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04101-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4101"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04101-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,25]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AM has received a speaker honorarium and travel grants from Roche, Abbvie and Janssen and has participated in advisory boards for Roche, Abbvie and Janssen. TB has received lecture fees from Janssen, Abbvie and Gilead\/Kite and has participated in advisory boards for Janssen. BSG reports none institutional research funding and is a consultant and\/or speaker bureau for Novartis, Amgen, Takeda, Alexion, Gilead and Shire. SM has received lecture fees and travel grants from Roche. AS participated in a speaker\u2019s bureau for Roche and Janssen, received travel grants from Roche, served on the advisory board of Celgene, Roche, Janssen and reports research funding from Roche and Gilead. ALG served on the advisory board of Roche, Celgene, Novartis, Gilead\/Kite and received grants from Celgene, Gilead\/Kite. JMS reports honoraria from Roche, Janssen, Gilead, Celgene, Novartis, Kern-pharma and Servier and has participated in advisory boards for Roche, Janssen, Gilead, Celgene, Novartis, Kern- Pharma and Celltrion. The remaining authors (ACC, LI, LE, JAS, MC, MTV, LM, OG and MS) have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participant who was alive at the moment of the study onset.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}